

Sanofi  
Form 6-K  
February 08, 2017

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of February 2017**

**Commission File Number: 001-31368**

**SANOFI**

**(Translation of registrant's name into English)**

**54, rue La Boétie, 75008 Paris, FRANCE**

Edgar Filing: Sanofi - Form 6-K  
**(Address of principal executive offices)**

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F                      Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes                      No

If  Yes  marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):  
82-

In February 2017, Sanofi issued the press releases and the statement attached hereto as Exhibit 99.1, 99.2 and 99.3 which is incorporated herein by reference.

**Exhibit List**

Exhibit No.	Description
Exhibit 99.1	Press release dated February 1, 2017: Sanofi's Xyzal® Allergy 24HR Approved for Over-the-Counter Use in The United States
Exhibit 99.2	Genzyme Product Sales Statement for the Product Sales Measuring Period ended December 31, 2016
Exhibit 99.3	Press release dated February 8, 2017: Sanofi Delivers 2016 Sales and Business EPS Growth at CER

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: February 8, 2017

SANOFI

By /s/ Alexandra Roger

Name: Alexandra Roger

Title: Head of Securities Law and Capital Markets

**Exhibit Index**

Exhibit No.	Description
Exhibit 99.1	Press release dated February 1, 2017: Sanofi's Xyzal Allergy 24HR Approved for Over-the-Counter Use in The United States
Exhibit 99.2	Genzyme Product Sales Statement for the Product Sales Measuring Period ended December 31, 2016
Exhibit 99.3	Press release dated February 8, 2017: Sanofi Delivers 2016 Sales and Business EPS <sup>(1)</sup> Growth at CER <sup>(2)</sup>